Business Context and Reporting Period
This Form 6-K filing is for BiondVax Pharmaceuticals Ltd., a foreign private issuer, covering the month of June 2017. The report was filed on June 14, 2017. Note: The request metadata references "Scinai Immunotherapeutics Ltd.", but the filing text explicitly identifies the registrant as BiondVax Pharmaceuticals Ltd.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial statements or performance metrics.
Material Changes
The primary material change reported is a departure from the Board of Directors:
- Director Departure: On June 11, 2017, Ms. Irit Ben Ami ended her third term as an external director.
- Service History: Ms. Ben Ami served on the board for nine years and acted as the chairperson of the audit committee.
Guidance, Outlook, and Risks
The filing contains no guidance, financial outlook, management commentary on operations, or discussion of risks and contingencies. The document serves solely to disclose the change in board composition.
Key Facts for Investor Verification
- Verify the current composition of the Board of Directors following Ms. Ben Ami's departure.
- Confirm the appointment of a new chairperson for the audit committee, if applicable.
- Review subsequent filings for any financial updates, as this specific 6-K contains no financial data.